Investment
Features
FeesSafety
Academy
More
Pluang+

Hyperliquid's U.S. launch may take 10-12 months due to complex regulatory hurdles involving SEC and CFTC.

Market News
31 Aug 2026
Crypto news
View Source
Neutral
pluang ai news

Hyperliquid faces a 10-to-12-month regulatory process to enter the U.S. market, as it requires navigating complex jurisdictional issues between the SEC and CFTC. The Commodity Futures Trading Commission would likely oversee crypto perpetual futures tied to commodities, while the Securities and Exchange Commission would regulate contracts linked to securities. Establishing a compliant framework involves rulemaking, registration, and possibly new legislation, with political support but no clear timetable. This pathway, once created, could also enable other platforms like Coinbase and Kraken to offer similar products in the U.S.

More News

Scotiabank raises Palo Alto Networks price target to $430 after strong Q3 and growth outlook.

Scotiabank raises Palo Alto Networks price target to $430 after strong Q3 and growth outlook.

Scotiabank increased its price target for Palo Alto Networks to $430, suggesting a 13% upside from current levels, following a 30% surge in shares after strong Q3 results. The cybersecurity firm is expected to deliver robust Q4 performance and signif...

Analyst Insights
Bullish
1 hour ago
Fiserv stock downgraded amid lowered 2026 growth and profit forecasts, with shares expected to drop nearly 17%.

Fiserv stock downgraded amid lowered 2026 growth and profit forecasts, with shares expected to drop nearly 17%.

Fiserv faces a downgrade from Cantor Fitzgerald with a new price target of $53, down nearly 17% from its recent price of $63.80. The company cut its 2026 guidance, expecting flat to slightly negative organic growth and a 14.2% drop in earnings per sh...

Analyst Insights
Bearish
2 hours ago
BioMarin Pharma gains with analyst upgrade, patent deal, and $275M acquisition boosting growth.

BioMarin Pharma gains with analyst upgrade, patent deal, and $275M acquisition boosting growth.

BioMarin Pharmaceutical Inc. saw its stock gain momentum after Jefferies raised its price target to $105, signaling strong confidence in the biotech firm. The company secured new revenue streams through a patent settlement with Ascendis Pharma, earni...

Analyst Insights
Bullish
3 hours ago
Aehr Test Systems CEO sells $5.2M shares after stock price jumps 564%.

Aehr Test Systems CEO sells $5.2M shares after stock price jumps 564%.

Aehr Test Systems' CEO sold shares worth $5.2 million following a remarkable 564% increase in the company's stock price. This significant sale highlights the CEO capitalizing on the stock's strong rally. Investors may view this move as a signal about...

Market News
Neutral
3 hours ago
Zoomd Technologies beats EPS estimates with 11% revenue growth and strong financial health.

Zoomd Technologies beats EPS estimates with 11% revenue growth and strong financial health.

Zoomd Technologies Ltd. reported a second-quarter EPS of $0.01, surpassing analyst estimates of $0.0038, signaling better-than-expected profitability. Although quarterly revenue was $7.67 million, slightly below the $8.41 million forecast, the compan...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App